Loading…
Reported covered position: Deputy GC, Principal Deputy GC, Acting GC, HHS
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To designate the facility of the United States Postal Service located at 324 Washington Avenue, Suite 1 in Grand Haven, Michigan, as the "Ell Thomas Simantz Post Office Building".
Client: KANEKA PHARMA AMERICA, LLC · Firm: KING & SPALDING LLP
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 8999 (118th Cong.).
To designate the facility of the United States Postal Service located at 324 Washington Avenue, Suite 1 in Grand Haven, Michigan, as the "Ell Thomas Simantz Post Office Building".
Client: KANEKA PHARMA AMERICA, LLC · Firm: KING & SPALDING LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHOTOCURE, INC. via KING & SPALDING LLP
2025 · second_quarter · Q2
Advocacy related to Bladder cancer treatment and blue light cystoscopy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2025 · second_quarter · Q2
Source: Senate LDA
| OMEROS CORPORATION |
| 5 |
| 2014–2015 |
| MARINE POLYMER TECHNOLOGIES, INC. | 3 | 2015 |
| VENTEC LIFE SYSTEMS | 3 | 2021 |
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 8999 (118th Cong.).
Dialysis-Related Amyloidosis Treatment Act of 2024
Client: KANEKA PHARMA AMERICA, LLC · Firm: KING & SPALDING LLP
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment; H.R. 8999.
Dialysis-Related Amyloidosis Treatment Act of 2024
Client: KANEKA PHARMA AMERICA, LLC · Firm: KING & SPALDING LLP
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment; H.R. 8999.
Positioning the Election Assistance Commission for the Future Act of 2023
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Small Business Growth Act
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Housing Is a Human Right Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772 (116) and Medicare coverage of Amyloid PET
Housing Is a Human Right Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
Client: GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Ensuring Equal Access to Treatments Act of 2015
Client: OMEROS CORPORATION · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: OMEROS CORPORATION · Firm: KING & SPALDING LLP
Support of H.R. 1178, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of HR 1178, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: OMEROS CORPORATION · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2015
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Ensuring Equal Access to Treatments Act of 2014
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Advocacy in support of Medicare coverage for outpatient cancer drugs, including H.R. 4857, Ensuring Equal Access to Treatments Act of 2014
Ensuring Equal Access to Treatments Act of 2014
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Advocacy in support of Medicare coverage for outpatient cancer drugs, including H.R. 4857, Ensuring Equal Access to Treatments Act of 2014
Ensuring Equal Access to Treatments Act of 2014
Client: PHOTOCURE, INC. · Firm: KING & SPALDING LLP
Advocacy in support of Medicare coverage for outpatient cancer drugs, including H.R. 4857, Ensuring Equal Access to Treatments Act of 2014
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 8999 (118th Cong.).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PHOTOCURE, INC. via KING & SPALDING LLP
2025 · first_quarter · Q1
Advocacy related to Bladder cancer treatment and blue light cystoscopy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2025 · first_quarter · Q1
Advocacy in support of Medicare Coverage for Dialysis-Related Amyloidosis (DRA) Treatment. H.R. 8999 (118th Cong.).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
PHOTOCURE, INC. via KING & SPALDING LLP
2024 · fourth_quarter · Q4
Advocacy related to Bladder cancer treatment and blue light cystoscopy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2024 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment; H.R. 8999.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2024 · third_quarter · Q3
Advocacy related to Bladder cancer treatment and blue light cystoscopy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2024 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment; H.R. 8999.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2024 · second_quarter · Q2
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2024 · second_quarter · RA
Advocacy in support of Medicare Coverage for Outpatient Cancer Drugs
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2024 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2024 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2023 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2023 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2023 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2023 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2023 · first_quarter · 1T
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2022 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2022 · fourth_quarter · Q4
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2022 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2022 · third_quarter · Q3
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2022 · second_quarter · 2T
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2022 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2022 · second_quarter · Q2
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2022 · first_quarter · Q1
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2022 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2022 · first_quarter · Q1
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTEC LIFE SYSTEMS via KING & SPALDING LLP
2021 · fourth_quarter · Q4
Regulatory pricing changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2021 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2021 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2021 · fourth_quarter · Q4
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2021 · third_quarter · Q3
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2021 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2021 · third_quarter · Q3
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTEC LIFE SYSTEMS via KING & SPALDING LLP
2021 · third_quarter · Q3
Regulatory pricing changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2021 · second_quarter · Q2
Advocacy related to FDA regulation of bone growth stimulator devices
PHOTOCURE, INC. via KING & SPALDING LLP
2021 · second_quarter · Q2
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2021 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2021 · second_quarter · Q2
Advocacy on outpatient package payment and H.R. 3772 (116) and Medicare coverage of Amyloid PET
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VENTEC LIFE SYSTEMS via KING & SPALDING LLP
2021 · second_quarter · Q2
Regulatory pricing changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2021 · first_quarter · Q1
Advocacy related to FDA regulation of bone growth stimulator devices
PHOTOCURE, INC. via KING & SPALDING LLP
2021 · first_quarter · Q1
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS)
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2021 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2021 · first_quarter · Q1
Advocacy on outpatient package payment and H.R. 3772
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2020 · fourth_quarter · Q4
Advocacy related to FDA regulation of bone growth stimulator devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2020 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS)
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2020 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2020 · fourth_quarter · Q4
Advocacy on outpatient package payment and H.R. 3772
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2020 · third_quarter · Q3
Advocacy related to FDA regulation of bone growth stimulator devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2020 · third_quarter · Q3
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS)
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2020 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2020 · third_quarter · Q3
Advocacy on outpatient package payment and H.R. 3772
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2020 · second_quarter · Q2
Advocacy related to FDA regulation of bone growth stimulator devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2020 · second_quarter · Q2
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2020 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2020 · second_quarter · Q2
Advocacy on outpatient package payment and H.R. 3772
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2020 · first_quarter · Q1
Advocacy related to reimbursement of bone growth stimulator devices
Advocacy related to FDA regulation of bone growth stimulator devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2020 · first_quarter · Q1
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2020 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2020 · first_quarter · Q1
Advocacy on outpatient package payment and H.R. 3772
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GE HEALTHCARE PHARMACEUTICAL DIAGNOSTICS via KING & SPALDING LLP
2020 · first_quarter · RR
Advocacy on outpatient package payment and H.R. 3772
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy related to reimbursement of bone growth stimulator devices
PHOTOCURE, INC. via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · second_quarter · 2A
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2019 · first_quarter · Q1
Advocacy related to reimbursement of bone growth stimulator devices
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2018 · fourth_quarter · Q4
Advocacy related to reimbursement of bone growth stimulator devices
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2018 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · third_quarter · 3A
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · second_quarter · 2A
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHOTOCURE, INC. via KING & SPALDING LLP
2018 · third_quarter · Q3
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · third_quarter · Q3
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2018 · third_quarter · Q3
Advocacy related to reimbursement of bone growth stimulator devices
PHOTOCURE, INC. via KING & SPALDING LLP
2018 · second_quarter · Q2
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2018 · second_quarter · Q2
Advocacy related to reimbursement of bone growth stimulator devices
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · second_quarter · Q2
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KANEKA PHARMA AMERICA, LLC via KING & SPALDING LLP
2018 · second_quarter · RR
Advocacy in support of Medicare coverage for Dialysis-Related Amyloidosis (DRA) Treatment
PHOTOCURE, INC. via KING & SPALDING LLP
2018 · first_quarter · Q1
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BONE GROWTH STIMULATOR COALITION (INFORMAL COALITION) via KING & SPALDING LLP
2018 · first_quarter · Q1
Advocacy related to reimbursement of bone growth stimulator devices
PHOTOCURE, INC. via KING & SPALDING LLP
2017 · fourth_quarter · Q4
Advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEARTFLOW via KING & SPALDING LLP
2017 · fourth_quarter · Q4
Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2017 · fourth_quarter · Q4
Medicare enrollment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARTFLOW via KING & SPALDING LLP
2017 · third_quarter · Q3
Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2017 · third_quarter · Q3
Medicare enrollment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARTFLOW via KING & SPALDING LLP
2017 · second_quarter · Q2
Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2017 · second_quarter · Q2
Medicare enrollment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2017 · first_quarter · Q1
Medicare enrollment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARTFLOW via KING & SPALDING LLP
2017 · first_quarter · Q1
Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARTFLOW via KING & SPALDING LLP
2016 · fourth_quarter · Q4
Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2016 · fourth_quarter · Q4
Medicare enrollment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALERE, INC. via KING & SPALDING LLP
2016 · fourth_quarter · RR
Medicare enrollment
HEARTFLOW via KING & SPALDING LLP
2016 · fourth_quarter · RR
Medicare reimbursement
PHOTOCURE, INC. via KING & SPALDING LLP
2015 · third_quarter · 3A
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE